Abstracts tagged "rheumatoid arthritis (RA) and tyrosine kinase inhibition"

Abstract Number: 2000 • 2019 ACR/ARP Annual Meeting
Anti-inflammatory Effect of Novel Spleen Tyrosine Kinase Inhibitor, SKI-O-592, on Fibroblast-like Synoviocyte in Rheumatoid Arthritis and THP-1 Cell
Seon Uk Kim¹, Hyun Jung Yoo ², Shin Eui Kang ³, Ji soo Park ⁴, Ra Ham Kim ⁵, Jung-Ho Kim ⁶, Hae-Jun Hwang ⁶, Jin Kyun Park ⁷, Eun Young Lee ⁷ and Yeong-Wook Song ⁸, ¹Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine, Seoul National University, Seoul, Republic of Korea, ²Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology and College of Medicine, Seoul National University, Seoul, Repulbic of Korea, Seoul, Republic of Korea, ³Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology and College of Medicine, Seoul National University, Seoul, Republic of Korea, Seoul, Republic of Korea, ⁴Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea., Seoul, Republic of Korea, ⁵Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology and College of Medicine, Seoul National University, Seoul, Republic of Korea, Seoul, Republic of Korea, ⁶Oscotec Inc., Seongnam, Republic of Korea, ⁷Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, seoul, Republic of Korea, ⁸Seoul National University Hospital, Seoul, Republic of Korea
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease characterized by bone and cartilage destruction with leukocyte infiltration and activation at synovial tissue. The…
Abstract Number: 1826 • 2018 ACR/ARHP Annual Meeting
From Cancer to Autoimmunity : A New Model of Rheumatoid Arthritis Emerging from a Constitutional Genetic Approach Used in Low Penetrance Cancers
Geraldine Falgarone^1,2, Morad El Bouchtaoui³, Marcio Do Cruzeiro⁴, Christophe Leboeuf^5,6,7, Irmine Loisel-Ferreira^5,6, Carèle Frédonie⁷, Chrystophe Ferreira⁸, Rachida Ait El Far⁵, Marc Espié⁹, Bruno Cassinat¹⁰, Jean-Jacques Kiladjian¹¹, Jean-Paul Feugeas^12,13, Anne Janin^5,6,14 and Guilhem Bousquet^2,5,15, ¹HUPSSD, Avicenne Hospital, Rheumatology, APHP, Bobigny, France, ²Paris 13 University, SMBH, Bobigny, France, ³INSERM UMR-S 1165, PARIS, France, ⁴Plateforme de Recombinaison Homologue, Institut Cochin, INSERM U1016, Paris, France, ⁵INSERM UMR-S 1165, Paris, France, ⁶Université Paris Diderot, Paris, France, ⁷INSERM U944, Paris, France, ⁸Plateforme ANIMA5, Université Paris Descartes, Paris, France, ⁹Centre des Maladies du Sein, APHP, Hôpital Saint-Louis, Paris, France, ¹⁰Laboratoire de BIologie Cellulaire, APHP, Hôpital Saint-Louis, Paris, France, ¹¹Centre d'Inverstigation Clinique, APHP, Hôpital Saint-Louis, Paris, France, ¹²INSERM U1137, Paris, France, ¹³Département de Biologie, Université Franche-Comté, Besançon, France, ¹⁴Service de Pathologie, APHP, Hôpital Saint-Louis, Paris, France, ¹⁵Service d'Oncologie médicale, APHP, Hôpital Avicenne, Bobigny, France
Background/Purpose: High-speed technologies for genome sequencing have completely changed the study of disease genetics, but with limited knowledge of the functional value of most genetic…
Abstract Number: 503 • 2017 ACR/ARHP Annual Meeting
BMS-986195 Is a Highly Selective and Rapidly Acting Covalent Inhibitor of Bruton’s Tyrosine Kinase with Robust Efficacy at Low Doses in Preclinical Models of RA and Lupus Nephritis
JR Burke, KM Gillooly, MA Pattoli, L Cheng, S Skala, EM Heimrich, TL Taylor, C Pulicicchio, DW Kukral, T Petrone, IM Catlett, N Zheng, W Li, SH Watterson and JA Tino, Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: BMS-986195 is a potent, covalent, irreversible inhibitor of Bruton’s tyrosine kinase (BTK), a member of the Tec family of non-receptor tyrosine kinases essential in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].